Medical and substance-related comorbidity in bipolar disorder: Translational research and treatment opportunities

Dialogues in Clinical Neuroscience

Volumn 10, Issue 2, 2008, Pages 203-213

  McIntyre, Roger S ^a,b,c   Nguyen, Ha T ^b   Soczynska, Joanna K ^b   Lourenco, Maria Teresa C ^b   Woldeyohannes, Hanna O ^b   Konarski, Jakub Z ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Bipolar disorder; Diabetes mellitus; Medical comorbidity; Substance use comorbidity

Indexed keywords

GLUCOSE; INSULIN;

ALZHEIMER DISEASE; ARTHRITIS; ARTICLE; ASTHMA; BIPOLAR DISORDER; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL RESEARCH; COMORBIDITY; DEMENTIA; DIABETES MELLITUS; DYSLIPIDEMIA; ENDOCRINE DISEASE; GASTROINTESTINAL DISEASE; HEADACHE; HEPATITIS C; HOMEOSTASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; INJURY; KIDNEY DISEASE; LIVER DISEASE; LOW BACK PAIN; LUNG DISEASE; MEDLINE; METABOLIC SYNDROME X; MIGRAINE; MUSCULOSKELETAL DISEASE; NEOPLASM; NEUROBIOLOGY; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PANCREATITIS; PARKINSON DISEASE; PREVALENCE; PROSTATE HYPERTROPHY; SKIN DISEASE; STROKE; SUBSTANCE ABUSE; THYROID DISEASE; UROGENITAL TRACT DISEASE;

BIPOLAR DISORDER; COMORBIDITY; DIABETES MELLITUS; HUMANS; LUNG DISEASES; METABOLIC DISEASES; OBESITY; STRESS, PSYCHOLOGICAL; SUBSTANCE-RELATED DISORDERS;

EID: 47749095041     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (126)

1. McElroy SL, Altshuler LL, Suppes T, et al. Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder. Am J Psychiatry. 2001;158:420-426.
2. Kessler R. Comorbidity of unipolar and bipolar depression with other psychiatric disorders in a general population survey. In: Tohen M, ed. Comorbidity in Affective Disorders. New York, NY: Marcel Dekker Inc.; 1999:1-25.
3. McIntyre RS, Konarski JZ, Soczynska JK, et al. Medical comorbidity in bipolar disorder: implications for functional outcomes and health service utilization. Psychiatr Serv. 2006;57:1140-1144.
4. Simon NM, Otto MW, Wisniewski SR, et al. Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry. 2004;161:2222-2229.
5. Cassidy F, Ahearn EP, Carroll BJ. Substance abuse in bipolar disorder. Bipolar Disord. 2001;3:181-188.
6. McElroy SL, Strakowski SM, Keck PE, Jr, et al. Differences and similarities in mixed and pure mania. Compr Psychiatry. 1995;36:187-194.
7. Osby U, Brandt L, Correia N, et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58:844-850.
8. McIntyre RS, Soczynska JK, Beyer JL, et al. Medical comorbidity in bipolar disorder: re-prioritizing unmet needs. Curr Opin Psychiatry. 2007;20:406-416.
9. Fenn HH, Bauer MS, Alshuler L, et al. Medical comorbidity and health-related quality of life in bipolar disorder across the adult age span. J Affect Disord. 2005;86:47-60.
10. Kilbourne AM, Cornelius JR, Han X, et al. Burden of general medical conditions among individuals with bipolar disorder. Bipolar Disord. 2004;6:368-373.
11. Calabrese JR, Hirschfeld RM, Reed M, et al. Impact of bipolar disorder on a U.S. community sample. J Clin Psychiatry. 2003;64:425-432.
12. Oedegaard KJ, Fasmer OB. Is migraine in unipolar depressed patients a bipolar spectrum trait? J Affect Disord. 2005;84:233-242.
13. Hirschfeld RM, Calabrese JR, Weissman MM, et al. Screening for bipolar disorder in the community. J Clin Psychiatry. 2003;64:53-59.
14. Thompson WK, Kupfer DJ, Fagiolini A, et al. Prevalence and clinical correlates of medical comorbidities in patients with bipolar I disorder: analysis of acute-phase data from a randomized controlled trial. J Clin Psychiatry. 2006;67:783-788.
15. Beyer J, Kuchibhatla M, Gersing K, et al. Medical comorbidity in a bipolar outpatient clinical population. Neuropsychopharmacology. 2005;30:401-404.
16. Wang GJ, Volkow ND, Telang F, et al. Exposure to appetitive food stimuli markedly activates the human brain. Neuroimage. 2004;21:1790-1797.
17. Fagiolini A, Frank E, Scott JA, et al. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord. 2005;7:424-430.
18. Ruzickova M, Slaney C, Garnham J, et al. Clinical features of bipolar disorder with and without comorbid diabetes mellitus. Can J Psychiatry. 2003;48:458-461.
19. Cassidy F, Ahearn E, Carroll BJ. Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am J Psychiatry. 1999;156:1417-1420.
20. Regenold WT, Thapar RK, Marano C, et al. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord. 2002;70:19-26.
21. Fasmer OB. The prevalence of migraine in patients with bipolar and unipolar affective disorders. Cephalalgia. 2001;21:894-899.
22. Mahmood T, Romans S, Silverstone T. Prevalence of migraine in bipolar disorder. J Affect Disord. 1999;52:239-241.
23. Low NC, Du Fort GG, Cervantes P. Prevalence, clinical correlates, and treatment of migraine in bipolar disorder. Headache. 2003;43:940-949.
24. McIntyre RS, Konarski JZ, Wilkins K, et al. The prevalence and impact of migraine headache in bipolar disorder: results from the Canadian Community Health Survey. Headache. 2006;46:973-982.
25. Nakimuli-Mpungu E, Musisi S, Mpungu SK, et al. Primary mania versus HIV-related secondary mania in Uganda. Am J Psychiatry. 2006;163:1349-1354.
26. Carney CP, Jones LE. Medical comorbidity in women and men with bipolar disorders: a population-based controlled study. Psychosom Med. 2006;68:684-691.
27. Snowdon J. A retrospective case-note study of bipolar disorder in old age. Br J Psychiatry. 1991;158:485-490.
28. Shulman KI, Tohen M, Satlin A, et al. Mania compared with unipolar depression in old age. Am J Psychiatry. 1992;149:341-345.
29. Wylie ME, Mulsant BH, Pollock BG, et al. Age at onset in geriatric bipolar disorder. Effects on clinical presentation and treatment outcomes in an inpatient sample. Am J Geriatr Psychiatry. 1999;7:77-83.
30. Simon GE, Von Korff M, Saunders K, et al. Association between obesity and psychiatric disorders in the US adult population. Arch Gen Psychiatry. 2006 63:824-830.
31. Elmslie JL, Silverstone JT, Mann JI, et al. Prevalence of overweight and obesity in bipolar patients. J Clin Psychiatry. 2000;61:179-184.
32. McElroy SL, Frye MA, Suppes T, et al. Correlates of overweight and obesity in 644 patients with bipolar disorder. J Clin Psychiatry. 2002;63:207-213.
33. Wang PW, Sachs GS, Zarate CA, et al. Overweight and obesity in bipolar disorders. J Psychiatr Res. 2006;40:762-764.
34. Fagiolini A, Frank E, Houck PR, et al. Prevalence of obesity and weight change during treatment in patients with bipolar I disorder. J Clin Psychiatry. 2002;63:528-533.
35. Basile VS, Masellis M, McIntyre RS, et al. Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. J Clin Psychiatry. 2001;62(suppl 23):45-66.
36. McIntyre RS, Konarski JZ, Wilkins K, et al. Obesity in bipolar disorder and major depressive disorder: results from a national community health survey on mental health and well-being. Can J Psychiatry. 2006;51:274-280.
37. Strudsholm U, Johannessen L, Foldager L, et al. Increased risk for pulmonary embolism in patients with bipolar disorder. Bipolar Disord. 2005;7:77-81.
38. Valle J, Ayuso-Gutierrez JL, Abril A, et al. Evaluation of thyroid function in lithium-naive bipolar patients. Eur Psychiatry. 1999;14:341-345.
39. Krishnan KR. Psychiatric and medical comorbidities of bipolar disorder. Psychosom Med. 2005;67:1-8
40. Johannessen L, Strudsholm U, Foldager L, et al. Increased risk of hypertension in patients with bipolar disorder and patients with anxiety compared to background population and patients with schizophrenia. J Affect Disord. 2006;95:13-17.
41. Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry. 1998;55:580-592.
42. Hennekens CH, Hennekens AR, Hollar D, et al. Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 2005;150:1115-1121.
43. Pine DS, Goldstein RB, Wolk S, et al. The association between childhood depression and adulthood body mass index. Pediatrics. 2001;107:1049-1056.
44. McElroy S, Allison D, Bray G. Obesity and Mental Disorders. New York, NY: Taylor & Francis; 2006.
45. McIntyre RS, Konarski JZ, Yatham LN. Comorbidity in bipolar disorder: a framework for rational treatment selection. Hum Psychopharmacol. 2004;19:369-386.
46. McIntyre RS, Konarski JZ, Misener VL, et al. Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications. Ann Clin Psychiatry. 2005;17:83-93.
47. Redelmeier DA, Tan SH, Booth GL. The treatment of unrelated disorders in patients with chronic medical diseases. N Engl J Med. 1998;338:1516-1520.
48. Coodin S. Body mass index in persons with schizophrenia. Can J Psychiatry. 2001;46:549-555.
49. Elmslie JL, Mann JI, Silverstone JT, et al. Determinants of overweight and obesity in patients with bipolar disorder. J Clin Psychiatry. 2001 62:486-491.
50. Fagiolini A, Kupfer DJ, Houck PR, et al. Obesity as a correlate of outcome in patients with bipolar I disorder. Am J Psychiatry. 2003;160:112-117.
51. Fagiolini A, Kupfer DJ, Rucci P, et al. Suicide attempts and ideation in patients with bipolar I disorder. J Clin Psychiatry. 2004;65:509-514.
52. van Winkel R, De Hert A, Van Eyck D, et al. Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. Biol Psychiatry. 2008;10:342-348.
53. Garcia-Portilla MP, Saiz PA, Benabarre A, et al. The prevalence of metabolic syndrome in patients with bipolar disorder. J Affect Disord. 2008;106:197-201.
54. Kilbourne AM, Cornelius JR, Han X, et al. General-medical conditions in older patients with serious mental illness. Am J Geriatr Psychiatry. 2005;13:250-254.
55. Breslau N, Merikangas K, Bowden CL. Comorbidity of migraine and major affective disorders. Neurology. 1994;44(suppl 7):S17-S22.
56. Minden SL. Mood disorders in multiple sclerosis: diagnosis and treatment. J Neurovirol. 2000;6(suppl 2):S160-S167.
57. Edwards LJ, Constantinescu CS. A prospective study of conditions associated with multiple sclerosis in a cohort of 658 consecutive outpatients attending a multiple sclerosis clinic. Mult Scler. 2004;10:575-581.
58. Harden CL, Goldstein MA. Mood disorders in patients with epilepsy: epidemiology and management. CNS Drugs. 2002;16:291-302.
59. Post RM, Weiss SR. Convergences in course of illness and treatments of the epilepsies and recurrent affective disorders. Clin EEG Neurosci. 2004;35:14-24.
60. Cole DP, Thase ME, Mallinger AG, et al. Slower treatment response in bipolar depression predicted by lower pretreatment thyroid function. Am J Psychiatry. 2002;159:116-121.
61. Cassidy F, Ahearn EP, Carroll BJ. Thyroid function in mixed and pure manic episodes. Bipolar Disord. 2002;4:393-397.
62. Kessler RC, Crum RM, Warner LA, et al. Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Arch Gen Psychiatry. 1997;54:313-321.
63. Stinson FS, Grant BF, Dawson DA, et al. Comorbidity between DSM-IV alcohol and specific drug use disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Drug Alcohol Depend. 2005;80:105-116.
64. Baethge C, Baldessarini RJ, Khalsa HM, et al. Substance abuse in first-episode bipolar I disorder: indications for early intervention. Am J Psychiatry. 2005;162:1008-1010.
65. Vornik LA, Brown ES. Management of comorbid bipolar disorder and substance abuse. J Clin Psychiatry. 2006;67(suppl 7):24-30.
66. Porter RJ, Gallagher P, Thompson JM, et al. Neurocognitive impairment in drug-free patients with major depressive disorder. Br J Psychiatry. 2003;182:214-220.
67. McCall WV, Dunn AG. Cognitive deficits are associated with functional impairment in severely depressed patients. Psychiatry Res. 2003;121:179-184.
68. Landro NI, Stiles TC, Sletvold H. Neuropsychological function in nonpsychotic unipolar major depression. Neuropsychiatry Neuropsychol Behav Neurol. 2001;14:233-240.
69. Hugdahl K, Rund BR, Lund A, et al. Brain activation measured with fMRI during a mental arithmetic task in schizophrenia and major depression. Am J Psychiatry. 2004;161:286-293.
70. Bearden CE, Glahn DC, Monkul ES, et al. Patterns of memory impairment in bipolar disorder and unipolar major depression. Psychiatry Res. 2006;142:139-150.
71. Gualtieri CT, Johnson LG, Benedict KB. Neurocognition in depression: patients on and off medication versus healthy comparison subjects. J Neuropsychiatry Clin Neurosci. 2006;18:217-225.
72. DeBattista C. Executive dysfunction in major depressive disorder. Exp Rev Neurother. 2005;5:79-83.
73. Malhi GS, Lagopoulos J, Ward PB, et al. Cognitive generation of affect in bipolar depression: an fMRI study. Eur J Neurosci. 2004;19:741-754.
74. Clark L, Sarna A, Goodwin GM. Impairment of executive function but not memory in first-degree relatives of patients with bipolar I disorder and in euthymic patients with unipolar depression. Am J Psychiatry. 2005;162:1980-1982.
75. Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol. 2004;3:169-178.
76. McIntyre RS, Soczynska JK, Lewis GF, et al. Managing psychiatric disorders with antidiabetic agents: translational research and treatment opportunities. Expert Opin Pharmacother. 2006;7:1305-1321.
77. Reske-Nielsen E, Lundbaek K. Diabetic encephalopathy. diffuse and focal lesions of the brain in long-term diabetes. Acta Neurol Scand. 1963;39(suppl 4):273-290.
78. Ferguson SC, Blane A, Wardlaw J, et al. Influence of an early-onset age of type 1 diabetes on cerebral structure and cognitive function. Diabetes Care. 2005;28:1431-1437.
79. Brands AM, Kessels RP, de Haan EH, et al. Cerebral dysfunction in type 1 diabetes: effects of insulin, vascular risk factors and blood-glucose levels. Eur J Pharmacol. 2004;490:159-168.
80. den Heijer T, Vermeer SE, van Dijk EJ, et al. Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI. Diabetologia. 2003;46:1604-1610.
81. McEwen BS, Magarinos AM, Reagan LP. Studies of hormone action in the hippocampal formation: possible relevance to depression and diabetes. J Psychosom Res. 2002;53:883-890.
82. Shapiro E, Brown SD, Saltiel AR, et al. Short-term action of insulin on Aplysia neurons: generation of a possible novel modulator of ion channels. J Neurobiol. 1991;22:55-62.
83. Masters BA, Shemer J, Judkins JH, et al. Insulin receptors and insulin action in dissociated brain cells. Brain Res. 1987;417:247-256.
84. Shibata S, Liou SY, Ueki S, et al. Inhibitory action of insulin on suprachiasmatic nucleus neurons in rat hypothalamic slice preparations. Physiol Behav. 1986;36:79-81.
85. Wilson CJ, Finch CE, Cohen HJ. Cytokines and cognition - the case for a head-to-toe inflammatory paradigm. J Am Geriatr Soc. 2002;50:2041-2056.
86. Wilson CJ, Finch CE, Cohen HJ. Cytokines and cognition - the case for a head-to-toe inflammatory paradigm. J Am Geriatr Soc. 2002;50:2041-2056.
87. Laye S, Bluthe RM, Kent S, et al. Subdiaphragmatic vagotomy blocks induction of IL-1 beta mRNA in mice brain in response to peripheral LPS. Am J Physiol. 1995;268(5 Pt 2):R1327-R1331.
88. Hansen MK, Taishi P, Chen Z, et al. Vagotomy blocks the induction of interleukin-1beta (IL-1 beta) mRNA in the brain of rats in response to systemic IL-1beta. J Neurosci. 1998;18:2247-2253.
89. Zhou D, Kusnecov AW, Shurin MR, et al. Exposure to physical and psychological stressors elevates plasma interleukin 6: relationship to the activation of hypothalamic-pituitary-adrenal axis. Endocrinology. 1993;133:2523-2530.
90. Takaki A, Huang QH, Somogyvari-Vigh A, et al. Immobilization stress may increase plasma interleukin-6 via central and peripheral catecholamines. Neuroimmunomodulation. 1994;1:335-342.
91. Rush AJ, Giles DE, Schlesser MA, et al. The dexamethasone suppression test in patients with mood disorders. J Clin Psychiatry. 1996;57:470-484.
92. Musselman DL, Betan E, Larsen H, et al. Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment. Biol Psychiatry. 2003;54:317-329.
93. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27:24-31.
94. Khanzode SD, Dakhale GN, Khanzode SS, et al. Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep. 2003;8:365-370.
95. Reichenberg A, Yirmiya R, Schuld A, et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry. 2001;58:445-452.
96. Licinio J, Wong ML. The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol Psychiatry. 1999;4:317-327.
97. Capuron L, Miller AH. Cytokines and psychopathology: lessons from interferon-alpha. Biol Psychiatry. 2004;56:819-824.
98. Strakowski SM, DelBello MP, Fleck DE, et al. Effects of co-occurring alcohol abuse on the course of bipolar disorder following a first hospitalization for mania. Arch Gen Psychiatry. 2005;62:851-858.
99. Strakowski SM, DelBello MP, Fleck DE, et al. Effects of co-occurring cannabis use disorders on the course of bipolar disorder after a first hospitalization for mania. Arch Gen Psychiatry. 2007;64:57-64.
100. Volkow ND, Wise RA. How can drug addiction help us understand obesity? Nat Neurosci. 2005;8:555-560.
101. Wang GJ, Volkow ND, Thanos PK, et al. Similarity between obesity and drug addiction as assessed by neurofunctional imaging: a concept review. J Addict Dis. 2004;23:39-53.
102. McElroy SL, Kotwal R, Malhotra S, et al. Are mood disorders and obesity related? A review for the mental health professional. J Clin Psychiatry. 2004;65:634-651.Quiz 730. Review.
103. Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry. 2005;162:1403-1413.
104. Schwartz MW, Woods SC, Porte D, Jr, et al. Central nervous system control of food intake. Nature. 2000;404:661-671.
105. Volkow N, Li TK. The neuroscience of addiction. Nat Neurosci. 2005;8:1429-1430.
106. Thiele TE, Navarro M, Sparta DR, et al. Alcoholism and obesity: overlapping neuropeptide pathways? Neuropeptides. 2003;37:321-337.
107. Kraus T, Reulbach U, Bayerlein K, et al. Leptin is associated with craving in females with alcoholism. Addict Biol. 2004;9:213-219.
108. Kiefer F, Jahn H, Jaschinski M, et al. Leptin: a modulator of alcohol craving? Biol Psychiatry. 2001;49:782-787.
109. Martel P, Fantino M. Mesolimbic dopaminergic system activity as a function of food reward: a microdialysis study. Pharmacol Biochem Behav. 1996;53:221-226.
110. Hoebel BG. Brain neurotransmitters in food and drug reward. Am J Clin Nutr. 1985;42(5 suppl):1133-1150.
111. Blum K, Cull J, Braverna E, et al. Reward deficiency syndrome. Am Sci. 1996;84:132-139.
112. Hernandez L, Hoebel BG. Food reward and cocaine increase extracellular dopamine in the nucleus accumbens as measured by microdialysis. Life Sci. 1988;42:1705-1712.
113. Volkow ND, Fowler JS, Wang GJ, et al. Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. Synapse. 1993;14:169-177.
114. Wang GJ, Volkow ND, Fowler JS, et al. Dopamine D2 receptor availability in opiate-dependent subjects before and after naloxone-precipitated withdrawal. Neuropsychopharmacology. 1997;16:174-182.
115. Hietala J, West C, Syvalahti E, et al. Striatal D2 dopamine receptor binding characteristics in vivo in patients with alcohol dependence. Psychopharmacology (Berl). 1994;116:285-290.
116. Wang GJ, Volkow ND, Logan J, et al. Brain dopamine and obesity. Lancet. 2001;357:354-357.
117. Volkow ND, Wang GJ, Maynard L, et al. Brain dopamine is associated with eating behaviors in humans. Int J Eat Disord. 2003;33:136-142.
118. McIntyre RS, Mancini DA, Basile VS. Mechanisms of antipsychotic-induced weight gain. J Clin Psychiatry. 2001;62(suppl 23):232-239.
119. McIntyre RS, McElroy SL, Konarski JZ, et al. Substance use disorders and overweight/obesity in bipolar I disorder: preliminary evidence for competing addictions. J Clin Psychiatry. 2007;68:1352-1357.
120. MacKinnon DF, Zandi PP, Gershon E, et al. Rapid switching of mood in families with multiple cases of bipolar disorder. Arch Gen Psychiatry. 2003;60:921-928.
121. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447:661-678.
122. Suppes T, Dennehy EB, Hirschfeld RM, et al. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry. 2005;66:870-886.
123. Yatham LN, Kennedy SH, O'Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord. 2005;7(suppl 3):5-69.
124. Bauer MS. An evidence-based review of psychosocial treatments for bipolar disorder. Psychopharmacol Bull. 2001;35:109-134.
125. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002;159(4 suppl):1-50.
126. Sajatovic M, Blow FC, Ignacio RV. Psychiatric comorbidity in older adults with bipolar disorder. Int J Geriatr Psychiatry. 2006;21:582-587.